Detail akcie Formycon online

Business Summary: Formycon AG is a Germany based Company. The Company is engaged in providing biosimilar drugs and formulations. The Company focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Formycon AG revenues decreased 67% to EUR9M. Net loss applicable to common stockholders increased from EUR10.1M to EUR54.2M. Revenues reflect FYB202 segment decrease of 77% to EUR2.6M, FYB201 segment decrease of 71% to EUR2.4M, FYB203 segment decrease of 46% to EUR4M, Switzerland (Country) segment decrease of 77% to EUR4.5M, Germany (Country) segment decrease of 39% to EUR4.5M.